A Randomised, Double-blind, Placebo-controlled, Efficacy and Safety Cross-over Study of 4 Weeks of Oral BI 671800 ED 200 mg Twice Daily or 400 mg Once Daily Administered in the Morning (AM) or Evening (PM), in Symptomatic Asthma Patients on Inhaled Fluticasone Propionate MDI

Trial Profile

A Randomised, Double-blind, Placebo-controlled, Efficacy and Safety Cross-over Study of 4 Weeks of Oral BI 671800 ED 200 mg Twice Daily or 400 mg Once Daily Administered in the Morning (AM) or Evening (PM), in Symptomatic Asthma Patients on Inhaled Fluticasone Propionate MDI

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Oct 2013

At a glance

  • Drugs BI 671800 (Primary) ; Fluticasone propionate
  • Indications Asthma
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Sep 2012 Primary endpoint 'Forced-expiratory-volume-in-1-second' has not been met, as reported in ERS abstract.
    • 04 Sep 2012 Results presented at the 22nd Annual Congress of the European Respiratory Society.
    • 11 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top